Rociletinib hydrobromide

Rociletinib hydrobromide (CO-1686 hydrobromide) is an orally delivered kinase inhibitor that specifically targets the mutant forms of EGFR including T790M, and the Ki values for EGFRL858R/T790M and EGFRWT are 21.5 nM and 303.3 nM, respectively.

Product Specifications

CAS Number

[1446700-26-0]

Product Name Alternative

CO-1686 (hydrobromide) ; AVL-301 hydrobromide; CNX-419 hydrobromide

UNSPSC

12352005

Target

EGFR

Type

Reference compound

Related Pathways

JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/CO-1686-hydrobromide.html

Purity

98.04

Solubility

DMSO : ≥ 59 mg/mL|H2O : < 0.1 mg/mL

Smiles

C=CC(NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(C(C)=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1)=O.[H]Br

Molecular Formula

C27H29BrF3N7O3

Molecular Weight

636.46

References & Citations

[1]Walter AO, et al. Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Cancer Discov. 2013 Sep 25.